An Open Label Study of Chronic Polyethyleneglycol3350 Use in Constipated Patients

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the safety of extended use of polyethyleneglycol3350 laxative in constipated patients.

• Phase: Phase 4

Details

• Lead Sponsor: Braintree Laboratories
• Treatments: Polyethylene glycol 3350

Criteria

Inclusion Criteria:

• Inclusion Criteria:

• Male or female outpatients at least 18 years of age

• Constipated according to ROME I criteria

• If female and of childbearing potential, patient must be surgically sterilized or using oral contraceptives, depot contraceptives, intrauterine device, or testifies that she is monogamous with a vasectomized partner, or practices abstinence and will continue to do so during the duration of study

• Are otherwise in good health, as judged by a physical examination

• In the investigator's judgment, patient is mentally competent to sign an instrument of informed consent

Exclusion Criteria:

• Patients with heme positive stool at screening. Patients with heme positive stool that can be attributed to hemorrhoids or anal fissures are eligible for inclusion.

• Patients with hypo- or hyperthyroidism as determined by history, or screening TSH results.

• Patients with known or suspected perforation or obstruction.

• History of gastric retention, inflammatory bowel disease, bowel resection, or colostomy.

• Patients with a known history of organic cause for their constipation.

• Patients meeting the ROME definition of Irritable Bowel Syndrome

• Patients currently taking any of the following medications that are known to effect bowel habits:

• Antidiarrheals

• Antacids containing magnesium or aluminum salts

• Anticholinergics

• Antispasmodic agents

• Erythromycin and other macrolides

• Octreotide

• Lotronex, Zofran, or other 5-HT3 antagonists

• Zelnorm, or other 5-HT4 agonists

• Opiods/narcotic analgesics

• Prokinetics

• Serotonin re-uptake inhibitors or tricyclic antidepressants

• Calcium antagonists

• Patients who are breastfeeding, pregnant, or intend to become pregnant during the study.

• Female patients of childbearing potential who refuse a pregnancy test.

• Patients with a known allergy to polyethyleneglycol.

• Patients who, in the opinion of the investigator, should not be included in the study for any reason, including inability to follow study procedures.

• Patients who, within the past 30 days have participated in an investigational clinical study